Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryotaro Nakamura

Showing results (61-70 of 244) with videos related to

Pageof 25
Sort By:
Journal of the National Cancer Institute|August 18, 2022
Social Vulnerability and Risk of Nonrelapse Mortality After Allogeneic Hematopoietic Cell TransplantationRusha Bhandari, Jennifer Berano Teh, Tianhui He, et al.
Blood|August 15, 2002
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromeYogen Saunthararajah, Ryotaro Nakamura, Jun-Mo Nam, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 2, 2019
Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria ClonesMatthew Mei, Rohan Gupta, Margaret O'Donnell, et al.
Transplantation|August 27, 2019
Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA MismatchMonzr M Al Malki, Ketevan Gendzekhadze, Dongyun Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2021
Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell TransplantationEllen K Chang, Dayana Chanson, Jennifer Berano Teh, et al.
Stem Cell Research & Therapy|April 19, 2023
The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective studyDat Ngo, Jason Chen, Jose Tinajero, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2006
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphomaRoberto Rodriguez, Auayporn Nademanee, Nora Ruel, et al.
Blood|July 13, 2013
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)Wael Saber, Corey S Cutler, Ryotaro Nakamura, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 28, 2014
Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methodsWael Saber, Jennifer Le Rademacher, Mikkael Sekeres, et al.
BMC Cancer|May 1, 2023
Feasibility of implementing a supervised telehealth exercise intervention in frail survivors of hematopoietic cell transplantation: a pilot randomized trialKyuwan Lee, Justin Shamunee, Lanie Lindenfeld, et al.
Pageof 25

Showing results (61-70 of 244) with videos related to

Sort By:
Pageof 25
Journal of the National Cancer Institute|August 18, 2022
Social Vulnerability and Risk of Nonrelapse Mortality After Allogeneic Hematopoietic Cell TransplantationRusha Bhandari, Jennifer Berano Teh, Tianhui He, et al.
Blood|August 15, 2002
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromeYogen Saunthararajah, Ryotaro Nakamura, Jun-Mo Nam, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 2, 2019
Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria ClonesMatthew Mei, Rohan Gupta, Margaret O'Donnell, et al.
Transplantation|August 27, 2019
Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA MismatchMonzr M Al Malki, Ketevan Gendzekhadze, Dongyun Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2021
Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell TransplantationEllen K Chang, Dayana Chanson, Jennifer Berano Teh, et al.
Stem Cell Research & Therapy|April 19, 2023
The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective studyDat Ngo, Jason Chen, Jose Tinajero, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2006
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphomaRoberto Rodriguez, Auayporn Nademanee, Nora Ruel, et al.
Blood|July 13, 2013
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)Wael Saber, Corey S Cutler, Ryotaro Nakamura, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 28, 2014
Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methodsWael Saber, Jennifer Le Rademacher, Mikkael Sekeres, et al.
BMC Cancer|May 1, 2023
Feasibility of implementing a supervised telehealth exercise intervention in frail survivors of hematopoietic cell transplantation: a pilot randomized trialKyuwan Lee, Justin Shamunee, Lanie Lindenfeld, et al.
Pageof 25